ML19217A255: Difference between revisions
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
StriderTol (talk | contribs) (Created page by program invented by StriderTol) |
||
(One intermediate revision by the same user not shown) | |||
Line 15: | Line 15: | ||
=Text= | =Text= | ||
{{#Wiki_filter:United States of America Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or | {{#Wiki_filter:EXPORT LICENSE NRC LICENSE NO.: XMAT433/02 United States of America Page 1 of 4 Nuclear Regulatory Commission NRC DOCKET NO.: 11006181 Washington, D.C. 20555 LICENSE EXPIRES: May 31, 2024 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein. | ||
LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) | |||
production or utilization facilities listed below, subject to the terms and conditions herein. | Cambridge Isotope Laboratories, Inc. See following page(s) 50 Frontage Road Andover, MA 01810 Attn: Gary Ionta INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) OTHER U.S. PARTY(IES) TO EXPORT See following page(s) Cambridge Isotope Laboratories, Inc. | ||
50 Frontage Road Andover, MA 01810 (supplier/distributer) | |||
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)OTHER U.S. PARTY(IES) TO EXPORT | |||
APPLICANT'S | APPLICANT'S | ||
==REFERENCE:== | ==REFERENCE:== | ||
Application dated 03/27/2019 ULTIMATE DESTINATIONS: Republic of Korea QUANTITY(IES) DESCRIPTION OF MATERIAL(S) OR FACILITY(IES) | |||
This license is amended to: 1) include 10 additional ultimate consignees, and 2) extend the date of expiration from January 1, 2022 to May 31, 2024. | |||
The licensee is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of original export license XMAT433. | |||
Neither this license nor any right under this license shall be THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of 1954, as Digitally signed by Peter J. | |||
Peter J. Habighorst Habighorst amended, and the Energy Reorganization Act of 1974. SIGNATURE: Date: 2019.08.02 10:58:03 -04'00' Peter J. Habighorst, Acting Deputy Director This license is subject to the right of recapture or control NAME AND TITLE: | |||
Office of International Programs by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of DATE OF ISSUANCE: August 02, 2019 the NRC. | |||
EXPORT LICENSE | |||
XMAT433/02 Page 2 of 4 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | |||
: 1. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 2. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 3. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 4. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 5. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
1.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | : 6. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
2.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | : 7. | ||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
3.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
4.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
5.(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
6. | |||
3.(for distribution to ultimate consignees) | XMAT433/02 Page 3 of 4 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | ||
: 8. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 9. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 10. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 11. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 12. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
: 13. | |||
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets) | |||
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | |||
: 1. | |||
(for distribution to ultimate consignees) | |||
4.(for distribution to ultimate consignees)}} | XMAT433/02 Page 4 of 4 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES): | ||
: 2. | |||
(for distribution to ultimate consignees) | |||
: 3. | |||
(for distribution to ultimate consignees) | |||
: 4. | |||
(for distribution to ultimate consignees)}} |
Latest revision as of 04:32, 2 February 2020
ML19217A255 | |
Person / Time | |
---|---|
Site: | 11006181 |
Issue date: | 08/02/2019 |
From: | Peter Habighorst NRC/OIP |
To: | Ionta G Cambridge Isotope Labs |
Savoy J | |
References | |
Download: ML19217A255 (4) | |
Text
EXPORT LICENSE NRC LICENSE NO.: XMAT433/02 United States of America Page 1 of 4 Nuclear Regulatory Commission NRC DOCKET NO.: 11006181 Washington, D.C. 20555 LICENSE EXPIRES: May 31, 2024 Pursuant to the Atomic Energy Act of 1954, as amended, and the Energy Reorganization Act of 1974 and the regulations of the Nuclear Regulatory Commission (NRC) issued pursuant thereto, and in reliance on the statements and representations herefore made by the licensee, a license is hereby issued to the licensee authorizing the export of the materials and/or production or utilization facilities listed below, subject to the terms and conditions herein.
LICENSEE ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES)
Cambridge Isotope Laboratories, Inc. See following page(s) 50 Frontage Road Andover, MA 01810 Attn: Gary Ionta INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES) OTHER U.S. PARTY(IES) TO EXPORT See following page(s) Cambridge Isotope Laboratories, Inc.
50 Frontage Road Andover, MA 01810 (supplier/distributer)
APPLICANT'S
REFERENCE:
Application dated 03/27/2019 ULTIMATE DESTINATIONS: Republic of Korea QUANTITY(IES) DESCRIPTION OF MATERIAL(S) OR FACILITY(IES)
This license is amended to: 1) include 10 additional ultimate consignees, and 2) extend the date of expiration from January 1, 2022 to May 31, 2024.
The licensee is authorized to export a cumulative total of 10,000 kilograms of deuterium, in the form of deuterium oxide, deuterium gas, and other compounds. The cumulative total starts from the issuance of original export license XMAT433.
Neither this license nor any right under this license shall be THIS LICENSE IS INVALID UNLESS SIGNED BELOW assigned or otherwise transferred in violation of the BY AUTHORIZED NRC REPRESENTATIVE provisions of the Atomic Energy Act of 1954, as Digitally signed by Peter J.
Peter J. Habighorst Habighorst amended, and the Energy Reorganization Act of 1974. SIGNATURE: Date: 2019.08.02 10:58:03 -04'00' Peter J. Habighorst, Acting Deputy Director This license is subject to the right of recapture or control NAME AND TITLE:
Office of International Programs by Section 108 of the Atomic Energy Act of 1954, as amended, and to all the other provisions of said Acts, now or hereafter in effect and to all valid rules and regulations of DATE OF ISSUANCE: August 02, 2019 the NRC.
EXPORT LICENSE
XMAT433/02 Page 2 of 4 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 1.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 2.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 3.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 4.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 5.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 6.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 7.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
XMAT433/02 Page 3 of 4 ULTIMATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 8.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 9.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 10.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 11.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 12.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
- 13.
(for non-nuclear end use in the medical, pharmaceutical, chemical, and industrial markets)
INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 1.
(for distribution to ultimate consignees)
XMAT433/02 Page 4 of 4 INTERMEDIATE CONSIGNEE(S) IN FOREIGN COUNTRY(IES):
- 2.
(for distribution to ultimate consignees)
- 3.
(for distribution to ultimate consignees)
- 4.
(for distribution to ultimate consignees)